United Story

<div class='circular--portrait' style='background:#8B008B;color: #f7f7f7;font-size:4em;'>UT</div>
UTHR -- USA Stock  

USD 203.84  0.11  0.05%

Today's article will sum up United Therapeutic. We will analyze why it could be a much better year for United Therapeutic shareholders. United Therapeutic is at this time traded for 172.38. The entity has historical hype elasticity of 0.9. The average price elasticity to hype of competition is about -0.65. The firm is anticipated to increase in value after the next headline, with the price going to jump to 173.28. The average volatility of media hype impact on the company stock price is about 93.95%. The price gain on the next news is estimated to be 0.52%, whereas the daily expected return is at this time at 0.42%. The volatility of related hype on United Therapeutic is about 129.9% with expected price after next announcement by competition of 171.73 Given the investment horizon of 30 days the next anticipated press release will be in about 10 days.
Published over a month ago
View all stories for United Therapeutic | View All Stories
Is United Therapeutic (NASDAQ:UTHR) gaining more confidence from retail investors?
On a scale of 0 to 100, United Therapeutic holds a performance score of 14. The entity has a beta of 1.2634, which indicates a somewhat significant risk relative to the market. Let's try to break down what United's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, United Therapeutic will likely underperform. Although it is vital to follow United Therapeutic current price movements, it is good to be conservative about what you can do with the information regarding equity historical returns. The philosophy towards measuring future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By inspecting United Therapeutic technical indicators, you can presently evaluate if the expected return of 0.42% will be sustainable into the future. Please operates United Therapeutic coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to make a quick decision on whether United Therapeutic existing price patterns will revert.
The successful prediction of United Therapeutic stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as United Therapeutic, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of United Therapeutic based on United Therapeutic hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to United Therapeutic's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to United Therapeutic's related companies.

Use Technical Analysis to project United expected Price

United Therapeutic technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of United Therapeutic technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of United Therapeutic trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for United Therapeutic, but it might be worth checking our own buy vs. sell analysis

What is the case for United Therapeutic Investors

The company reported the previous year's revenue of 1.41 B. Net Income was 468.6 M with profit before overhead, payroll, taxes, and interest of 1.33 B.
 2018 2020 2021 (projected)
PPandE Turnover2.611.812.04
Calculated Tax Rate22.3620.1324.52

Cost of Revenue Breakdown

United Therapeutic Cost of Revenue yearly trend continues to be relatively stable with very little volatility. Cost of Revenue is likely to drop to about 56 M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. United Therapeutic Cost of Revenue is relatively stable at the moment as compared to the past year. United Therapeutic reported last year Cost of Revenue of 65.43 Million
201188.9 Million
2012119.3 Million
2013131.13 Million
2014125.9 Million
201569 Million
201672.7 Million
202065.43 Million
202156.04 Million

How will United retail investors react to the next fall?

Coefficient of variation is down to 614.91. It may connote a possible volatility fall. United Therapeutic has relatively low volatility with skewness of 0.12 and kurtosis of 0.41. However, we advise all investors to independently investigate United Therapeutic to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure United Therapeutic's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact United Therapeutic's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on United Therapeutic Investment

While some firms in the biotechnology industry are either recovering or due for a correction, United Therapeutic may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 24th of February 2021, our research shows that United Therapeutic is a rather very steady investment opportunity with a low chance of financial distress in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our ongoing 30 days buy-or-sell advice on the enterprise is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of United Therapeutic. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com